Therapeutic approaches to Alzheimer's disease.
Several recent advances have provided new insights and possibilities in defining therapeutic targets for Alzheimer's disease. Of particular importance is the identification of the beta-secretase enzyme and the demonstration that immunization of a transgenic mouse model of Alzheimer's disease with Abeta(1-42) peptide can prevent or alleviate neuropathological features of the disease.
Thorsett
E D
ED
Elan Pharmaceuticals, South San Francisco, CA 94080, USA. ethorsett@elanpharma.com
Latimer
L H
LH
D000544:Alzheimer Disease / Q000201:enzymology / Q000628:therapy*; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000276:immunology; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism; D004195:Disease Models, Animal; D010450:Endopeptidases; D006801:Humans; D007114:Immunization; D051379:Mice; D008822:Mice, Transgenic; D015394:Molecular Structure; D010446:Peptide Fragments / Q000276:immunology; D058225:Plaque, Amyloid / Q000378:metabolism
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509284:BACE2 protein, human; C509280:BACE1 protein, human; C509282:Bace1 protein, mouse